A study found that a new once-weekly basal insulin injection holds similar efficacy, safety and lower rate of low blood sugar episodes in comparison with daily basal insulin. These results were from a phase 2 clinical trial presented at ENDO 2021 conference which discussed an investigational drug called basal insulin Fc (BIF) with insulin degludec, “a commercially available long-lasting daily insulin, in patients with type 2 diabetes”.
Learn more about T2 Diabetes:
"These study results demonstrate that BIF has promise as a once-weekly basal insulin and could be an advancement in insulin therapy," said Juan Frias, M.D., the study's principal investigator and the medical director of the National Research Institute in Los Angeles, Calif.
"Based on our promising data, further research with BIF has been initiated in patients with type 1 diabetes and other type 2 diabetes patient populations," Frias said.
Source: Science Daily